論文

査読有り 国際誌
2020年

Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study.

Neuropsychiatric disease and treatment
  • Aiichiro Nakajima
  • ,
  • Ayako Kanie
  • ,
  • Masaya Ito
  • ,
  • Naotsugu Hirabayashi
  • ,
  • Fumi Imamura
  • ,
  • Yoshitake Takebayashi
  • ,
  • Masaru Horikoshi

16
開始ページ
2135
終了ページ
2142
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.2147/NDT.S263537

Purpose: Benzodiazepines (BZDs) are prescribed to treat psychiatric diseases. However, many guidelines recommend limiting the use of BZDs because of side effects and lack of evidence regarding long-term efficacy. Moreover, reducing BZDs' use is difficult because of dependency and the severity of withdrawal symptoms. The efficacy of cognitive behavioral therapy (CBT) for mood and anxiety disorders has been demonstrated. However, there is scant evidence that CBT has effectively reduced BZDs use, especially in Japan, where the BZDs prescription rate is high. Therefore, we sought to examine the impact of CBT on reducing BZDs use in a Japanese psychiatric setting. Patients and Methods: Participants were outpatients with mood and anxiety disorders who were prescribed BZD anxiolytics. We retrospectively reviewed changes in BZD anxiolytics prescription dosages during CBT (66 patients; mean number of CBT sessions, 14.6) from our hospital record between April 2015 and September 2017. We checked prescriptions at four time points: at first interview for judging adaptation of CBT (baseline), at the first CBT session, at the last CBT session, and 3 months after the last CBT session. Results: A total of 13 of 66 patients discontinued BZD anxiolytics during CBT, and 21 of 66 reduced their prescribed dosage by 50%. The association between discontinuation and dose-reduction and assessment period was modeled simultaneously using Bayesian hierarchical hurdle model. Results from the modeling showed a significant discontinuation at post-CBT and at 3 months post-CBT session compared to baseline (estimated median odds ratio [OR] post-CBT = 9.79 [95% CI: 4.65-20.45]; OR at 3 months post-CBT = 11.53 [95% CI: 6.06-22.33]). Moreover, a significant dose reduction was observed post-intervention (estimated median relative risk = 0.845 [95% CI: 0.729-0.982]), with a median reduction of 1.7 mg (diazepam conversion) in BZD use. Conclusion: Our results suggest that CBT possibly aids in reducing and discontinuing BZD anxiolytics use for Japanese patients.

リンク情報
DOI
https://doi.org/10.2147/NDT.S263537
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32982251
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509325
ID情報
  • DOI : 10.2147/NDT.S263537
  • PubMed ID : 32982251
  • PubMed Central 記事ID : PMC7509325

エクスポート
BibTeX RIS